

论著

注射用丹参总酚酸(冻干)对人CYP450酶和P-糖蛋白体外抑制作用及对大鼠CYP1A2和CYP3A体内诱导作用

胡冰^{1,2}, 段超慧², 岳浩浩², 马英丽 周大铮², 李德坤¹, 叶正良¹

1. 天士力之骄药业有限公司, 天津 300410;
2. 黑龙江中医药大学, 黑龙江 哈尔滨150040

收稿日期 2011-12-30 修回日期 2012-6-18 网络版发布日期 2013-2-21 接受日期

摘要 目的 探讨注射用丹参总酚酸(冻干)(SLI)对人CYP450酶和P-糖蛋白体外抑制作用以及对大鼠CYP1A2和CYP3A体内诱导作用。方法 ① 应用P450-Glo™ CYP450检测试剂盒,通过化学发光法测定SLI和经典抑制剂对细胞色素P4501A2(CYP1A2), CYP2D6, CYP3A4, CYP2C19和CYP2C9的IC₅₀值,通过比较SLI和经典抑制剂对相应细胞色素P450亚型的IC₅₀值来判断SLI对人CYP450酶的体外抑制作用。② Wistar大鼠分别iv给予SLI 3, 10和30 mg·kg⁻¹和诱导剂苯巴比妥钠20 mg·kg⁻¹,采用探针底物法,通过比较代谢产物的生成速率来评价SLI对大鼠CYP1A2和CYP3A的诱导作用。③ 应用ATP酶检测试剂盒,通过化学发光法测定ATP酶活性来评价SLI是否为P-gp的底物或抑制剂。结果 ① CYP1A2, CYP2C9, CYP2C19, CYP2D6和CYP3A4抑制剂的IC₅₀与SLI对其的IC₅₀ 进行比较(CYP1A2: 0.12 μmol·L⁻¹ vs 840 μmol·L⁻¹; CYP2C9: 3.362 μmol·L⁻¹ vs 704 μmol·L⁻¹; CYP2C19: 3.236 μmol·L⁻¹ vs 306 μmol·L⁻¹; CYP2D6: 0.117 μmol·L⁻¹ vs 2660 μmol·L⁻¹; CYP3A4: 0.078 μmol·L⁻¹ vs 1780 μmol·L⁻¹)。② 与空白对照组(86.4±6.3)nmol·g⁻¹·min⁻¹相比, SLI 3, 10和30 mg·kg⁻¹组CYP1A2活性分别为83.4±6.6, 82.5±4.0和(83.4±6.6)nmol·g⁻¹·min⁻¹。与空白对照组(16.1±0.9)nmol·g⁻¹·min⁻¹比较, SLI 3, 10和30 mg·kg⁻¹组CYP3A活性分别为15.7±0.6, 15.9±0.7和(15.9±1.0)nmol·g⁻¹·min⁻¹,无显著性差异。3 以临床血药浓度为依据设计的一系列浓度的SLI 0.0002, 0.0006, 0.002, 0.006, 0.017, 0.052, 0.156和0.468 g·L⁻¹的ATP酶活性分别与空白对照组进行比较(5.8, 5.3, 5.8, 5.5, 5.8, 5.2,, 5.8, 5.3, vs 5.75 μmol·g⁻¹·min⁻¹),无显著性差异。结论 SLI临床给药剂量既不能体外抑制人CYP1A2, CYP2D6, CYP3A4, CYP2C19和CYP2C9酶活性,也不能诱导大鼠CYP1A2和CYP3A,同时也不是P-gp的体外抑制剂或底物。

关键词 [注射用丹参总酚酸\(冻干\)](#) [P-糖蛋白](#) [细胞色素P450 CYP1A2](#) [细胞色素P450 CYP3A](#)

分类号 [R963](#)

扩展功能

本文信息

▶ [Supporting info](#)

▶ [PDF\(328KB\)](#)

▶ [\[HTML全文\]\(0KB\)](#)

▶ [参考文献](#)

服务与反馈

▶ [把本文推荐给朋友](#)

▶ [加入我的书架](#)

▶ [加入引用管理器](#)

▶ [复制索引](#)

▶ [Email Alert](#)

▶ [文章反馈](#)

▶ [浏览反馈信息](#)

相关信息

▶ [本刊中 包含“注射用丹参总酚酸\(冻干\)”的 相关文章](#)

▶ [本文作者相关文章](#)

· [胡冰](#)

· [段超慧](#)

· [岳浩浩](#)

· [马英丽 周大铮](#)

· [李德坤](#)

· [叶正良](#)

Inhibitory effect of total salvianolate lyophilized injection, a herbal preparation, on human cytochrome P450 and P-glycoprotein *in vitro* and inductive effect on rat CYP1A2 and CYP3A *in vivo*

HU Bing^{1,2}, DUAN Chao-hui², YUE Jie-hao², MA Ying-li², ZHOU Da-zheng¹, LI De-kun¹, YE Zheng-liang¹

1. Tasly Pride Pharmaceutical Co., Ltd., Tianjin 300410, China;
2. Heilongjiang University of Chinese Medicine, Harbin 150040, China

Abstract

OBJECTIVE To investigate the inhibitory effect of salvianolate lyophilized injection (SLI) on human cytochrome P450 (CYP450) and P-glycoprotein(P-gp) system *in vitro* and the inductive effect on rat CYP1A2 and CYP3A *in vivo*.

METHODS ① IC₅₀ of cytochrome P-4501A2(CYP1A2), CYP2C9, CYP2C19, CYP2D6 and CYP3A4 inhibitors was evaluated by chemiluminescence using P450-Glo™ Screening Systems. The inhibition on CYP450 *in vitro* from SLI was evaluated by IC₅₀. ② Wistar rats were sc given SLI 3, 10 and 30 mg·kg⁻¹ or inducer. The method of probe substrate was used for evaluating the induction of rat CYP1A2 and CYP3A from SLI by comparing the production rate of metabolites. ③ The ATPase activities of SLI were determined by ATPase assay kit, which can evaluate whether SLI is a substrate or inhibitor of P-gp. **RESULTS** ① IC₅₀ of inhibitors and SLI was compared (CYP1A2, 0.012 μmol·L⁻¹ vs 840 μmol·L⁻¹; CYP2C9, 3.362 μmol·L⁻¹ vs 704 μmol·L⁻¹; CYP2C19, 3.236 μmol·L⁻¹ vs 306 μmol·L⁻¹; CYP2D6, 0.117 μmol·L⁻¹ vs 2660 μmol·L⁻¹; and CYP3A4, 0.078 μmol·L⁻¹ vs 1780 μmol·L⁻¹). ② Compared with control group (86.4±6.3) nmol·g⁻¹·min⁻¹, the activities of rat CYP1A2 in SLI 3, 10 and 30 mg·kg⁻¹ groups were 83.3±6.6, 82.5±4.0 and (83.4±6.6)μmol·g⁻¹·min⁻¹, respectively. Compared with control group (16.1±0.9)nmol·g⁻¹·min⁻¹, the activities of rat

CYP3A in SLI 3, 10 and 30 mg • kg⁻¹ groups were 15.9±1.0, 15.9±0.7 and (15.7±0.6)nmol • g⁻¹ • min⁻¹(P<0.05). 3 ATPase activity of SLI 0.0002, 0.0006, 0.0002, 0.005, 0.017, 0.052, 0.156 and 0.468 g • L⁻¹ according to the clinical human blood-drug level was compared with that in control group, respectively (5.8, 5.3, 5.8, 5.5, 5.8, 5.2, 5.8, and 5.3 vs 5.8 μmol • g⁻¹ • min⁻¹), but there was no significant difference. **CONCLUSION** SLI may neither induce rat CYP1A2 or CYP3A *in vivo*, nor inhibit human CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 *in vitro*. It is not a potential substrate or inhibitor for human P-gp *in vitro*.

Key words [salvianolate lyophilized injection](#) [P-glycoprotein](#) [cytochrome P-450 CYP1A2](#)
[cytochrome P-450 CYP3A](#)

DOI: 10.3867/j.issn.1000-3002.2013.01.002

通讯作者 叶正良,Tel:13602056330,E-mail:andrea1113@yahoo.cn andrea1113@yahoo.cn